SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-061524
Filing Date
2023-03-06
Accepted
2023-03-06 16:55:55
Documents
12
Period of Report
2023-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d410993d8k.htm   iXBRL 8-K 24610
  Complete submission text file 0001193125-23-061524.txt   149550

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20230301.xsd EX-101.SCH 2822
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20230301_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20230301_pre.xml EX-101.PRE 11689
6 EXTRACTED XBRL INSTANCE DOCUMENT d410993d8k_htm.xml XML 3489
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 23709664
SIC: 2836 Biological Products, (No Diagnostic Substances)